Xenetic Biosciences updates investor presentation on Santersus share exchange, outlines pro forma valuation and 2027–2029 milestones
1分未満で読めます
Xenetic Biosciences released an updated investor presentation on its proposed share exchange with Santersus, outlining an illustrative ~85%/15% pro‑forma ownership split, estimated $141M valuation for Santersus and key clinical and regulatory milestones through 2029.
Key Highlights:
- Filed Item 7.01: furnished investor presentation on pending share exchange with Santersus; proxy and S‑1 to be filed with the SEC.
- Transaction terms (illustrative): Santersus valuation ~$141M (~85% post‑close) and Xenetic valuation ~$21M (~15% pre‑merger), subject to exchange ratio and adjustments.
- Combined company expected to list on Nasdaq under ticker SNTS; Santersus to become wholly owned subsidiary and operating business.
- Target close: Q4 2026 (subject to stockholder approvals and customary conditions); timelines include pivotal starts, interim readouts and regulatory submissions 2027–2029.
- Pipeline and milestones: NucleoCapture pivotal sepsis study (up to 350 pts) with interim analysis Q4 2027 and EU launch potential Q2 2028; SLE, liver transplant and DNase/LBCL programs with multiple readouts and regulatory plans through 2029.
Original SEC Filing: Xenetic Biosciences, Inc. [ XBIO ] - 8-K - Sep. 23, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.